the government satisfied with the “success” of its immunization campaign among infants

2023-09-26 18:25:08

The new preventive treatment once morest bronchiolitis has a very high level of support among parents of infants, welcomes the Ministry of Health, which announces adapting its strategy to protect children at risk as a priority.

An “exceptional success”, according to the Minister of Health Aurélien Rousseau. Deployed since Friday September 15 in France, the new preventive treatment once morest bronchiolitis “encounters a very high adherence rate among parents of infants”, welcomes the ministry in a press release.

“Non-compulsory preventive treatments generally have an adherence rate which varies between 5 and 10%. However, today, the adherence rates to this new preventive treatment now exceed 60%, and even reach 80%. in certain establishments,” the press release said.

Priority to maternity wards

Faced with this strong demand, and “in the interest of good management of available stocks”, the authorities are adapting their strategy “in order to prioritize protecting children most at risk of being hospitalized”.

From now on, the 50 mg version of Beyfortus treatment, intended for babies weighing less than five kilograms, will be reserved for maternity wards. Pharmacies will be able to continue to order the 100 mg version, which is intended for babies of greater weight.

This decision is justified by the fact that “infants under one month old are most at risk of developing a serious form of bronchiolitis”, explains the ministry, without mentioning the case of babies in this age group but already discharged. maternity.

Health+%26+Fitness%2CNews&episode_published_at=2023-09-15T04%3A00%3A01&episode_title=Bronchiolite%3A+le+traitement+pour+b%C3%A9b%C3%A9s+qui+va+changer+l%27hiver+des+parents&network=228028218708&podcast_title=Le+podcast+sant%C3%A9" data-img-src="https://images.bfmtv.com/oMNiD4vk9fOq83Rq2Zl4FWB3EWo=/0x0:0x0/180x0/podcast/podcasts/principale-339_1.png" data-title="Bronchiolite: le traitement pour bébés qui va changer l'hiver des parents" data-id="202309150059" data-podcast-nom="Le podcast santé">Bronchiolitis: the treatment for babies that will change parents’ winter

Hospitalizations “at a low level” but “increasing”

Beyfortus, developed by the Sanofi group, is a treatment which aims to prevent babies from being infected with the respiratory syncytial virus (RSV). The latter is the main cause of bronchiolitis.

This disease, which results in breathing difficulties, is generally not serious but can become complicated and lead to hospitalization. Every year it causes an epidemic which, last season, was particularly intense.

According to the latest data, dating from last week, hospitalizations linked to bronchiolitis are “at a low level” but “increasing”.

François Blanchard with AFP

1695770647
#government #satisfied #success #immunization #campaign #among #infants